MA
APYX icon

MCF Advisors’s Apyx Medical APYX Stock Holding History

MCF Advisors’s Portfolio APYX Stock Details APYX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-438
Closed -$2K – 825
2022
Q3 		$2K Buy
+438
New +$3.14K ﹤0.01% 664

Other funds holding APYX

ACM
Archon Capital Management Seattle, Washington $246M AUM 130.69% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
HKAM
Horizon Kinetics Asset Management New York $8.82B AUM 23.05% 1-Year Est. Return
PVI
Pura Vida Investments New York $37M AUM 63.54% 1-Year Est. Return
CPA
Cowen Prime Advisors New York $290M AUM 57.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

MCF Advisors's APYX Position: Q4 2022 in Review

MCF Advisors sold out of Apyx Medical (APYX) in Q4 2022, closing a stake of 438 shares — an estimated $2K sold.

MCF Advisors first reported a position in APYX in Q3 2022 and held it in 1 quarter. The position peaked at $2K in Q3 2022. 50 funds tracked by Wall St. Rank hold APYX as of Q4 2022.

  • MCF Advisors reported no remaining Apyx Medical position as of Q4 2022 after selling out during the quarter.
  • MCF Advisors sold 438 Apyx Medical shares in Q4 2022, an estimated $2K.
  • MCF Advisors first reported a position in Apyx Medical in Q3 2022 and held it in 1 quarter.
  • MCF Advisors's Apyx Medical position peaked at $2K in Q3 2022.
  • 50 funds tracked by Wall St. Rank held Apyx Medical as of Q4 2022.

Based on MCF Advisors's 13F filing for Q4 2022, filed 31 Jan 2023.